UNSPSC 51112604: Fotemustine

This classification denotes a nitrosourea compound with the molecular formula C9H19ClN3O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GQ7JL9P5I2, chemically known as phosphonic acid, (1-((((2-chloroethyl)nitrosoamino)carbonyl)amino)ethyl)-, diethyl ester but more generally known as fotemustine, which bears US NIH Compound Identifier 104799. European Medicines Agency schedules Fotemustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07809MIG.

UNSPSC 51112604 Fotemustine is a Commodity code covering a specific chemotherapy agent used in cancer treatment protocols. State and local governments procure fotemustine primarily through health departments, hospital systems, and public health agencies that operate oncology clinics and infusion centers. The drug is typically sourced as part of bulk pharmaceutical procurement for melanoma and other cancer treatment programs, often bundled with other specialty pharmaceuticals in larger health-care supply contracts or standalone specialty-drug agreements.

The source provides no recent state or local contract opportunities tagged to this code. Without visibility into active RFPs, RFQs, or IFBs for fotemustine procurement, the current market activity and geographic concentration cannot be assessed from the available data.